Neurocrine Biosciences' (NBIX) exposure to Food and Drug Administration or tariff-related concerns is relatively less compared with its peers, RBC Capital Markets analyst team said Monday in a research note.
Amid weakness in the broader sector and the analysts' expectations for the company's Ingrezza commercial franchise to remain "relatively solid and durable" in the longer term, the firm notes that the company's stock is trading "well below fundamental fair value" and offers a "buying opportunity."
The team upgraded the stock to outperform from sector perform and slightly reduced the price target to $137 from $138.
Price: 94.93, Change: +4.06, Percent Change: +4.47
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。